First published in Expert Opinion on Pharmacotherapy on 2011 Jul.
Expert Opin Pharmacother. 2011 Jul;12(10):1571-84. doi: 10.1517/14656566.2011.567266.
Authors: Forst T, Hanefeld M, Pfützner A
Treatment with pioglitazone in T2DM was shown to improve insulin resistance and blood glucose levels without increasing the risk of hypoglycemia. Beyond those metabolic activities, pioglitazone was shown to evolve anti-inflammatory and anti-atherogenic effects. It seems useful to combine different antidiabetic drugs based on the specific needs and contraindications in an individual patient. The treating of T2DM patients by addressing not only glucose control, but also the underlying pathophysiological etiology might help to improve patient prognosis in the long run, especially with regard to the vascular complications.
Download full article as Pdf file: